Liquidia’s Yutrepia revenue jumped 31% in Q2, surpassing Wall Street expectations amid competition with United Therapeutics.
Liquidia reported second-quarter Yutrepia sales of $170.4 million, a 31% increase from the prior year, exceeding analyst estimates. The growth reflects strong demand for its inhaled lung disease treatment amid rivalry with United Therapeutics’ Tyvaso.
In the first quarter, LQDA stock hit a record high after similarly beating sales forecasts. Yutrepia and Tyvaso target pulmonary hypertension, a market with limited therapeutic options.
Shares showed no immediate reaction in after-hours trading, though prior quarters saw breakout rallies following earnings beats.